None
Quote | Fulcrum Therapeutics Inc. (NYSE:FULC)
Last: | $ |
---|---|
Change Percent: | -3.21% |
Open: | $16.30 |
Close: | $15.68 |
High: | $16.30 |
Low: | $15.40 |
Volume: | 41,328 |
Last Trade Date Time: | 02/12/2020 04:43:03 pm |
News | Fulcrum Therapeutics Inc. (NYSE:FULC)
2024-06-14 14:38:51 ET Summary Avidity Biosciences, Inc.'s FORTITUDE trial of AOC 1020 in treating FSHD showed promising reductions in DUX4 gene expression and improvements in muscle function. The trial reported favorable safety and tolerability, with no serious adverse events or ...
CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today a...
Message Board Posts | Fulcrum Therapeutics Inc. (NYSE:FULC)
Subject | By | Source | When |
---|---|---|---|
znewcar1: $FULC 20% v1,358M c12.30 f52,051M H12.41 ML5.11 | znewcar1 | investorshangout | 01/10/2023 10:33:05 PM |
In some for a bounce play at $3.86 | ottoman | investorshub | 06/12/2022 5:03:11 PM |
what a great short today 25 bucks, just | NYCJR | investorshub | 08/11/2021 9:46:57 PM |
Also > The company reported $4.40 million in | crudeoil24 | investorshub | 08/10/2021 4:26:00 PM |
Way up premarket on sickle cell news. | axconth | investorshub | 08/10/2021 1:10:02 PM |
News, Short Squeeze, Breakout and More Instantly...
Fulcrum Therapeutics Inc. Company Name:
FULC Stock Symbol:
NYSE Market:
Fulcrum Therapeutics Inc. Website:
CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today a...
CAMBRIDGE, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today a...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...